EU gives narrower label to Apellis, Sobi’s PNH drugApellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Share XEU gives narrower label to Apellis, Sobi’s PNH drughttps://pharmaphorum.com/news/eu-gives-narrower-label-to-apellis-sobis-pnh-drug/
AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trialIt has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the new Share XAZ’s Alexion plans hit a snag as Ultomiris flunks ALS trialhttps://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/
Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHThe mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris, Share XEHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHhttps://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/
Apellis set to take on Alexion as FDA clears PNH drug EmpaveliApellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal Share XApellis set to take on Alexion as FDA clears PNH drug Empavelihttps://pharmaphorum.com/news/apellis-set-to-take-on-alexion-as-fda-clears-pnh-drug-empaveli/
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUSNHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to Share XScotland backs NHS use of Alexion’s Ultomiris for rare disease aHUShttps://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/
Alexion trials rare disease drug Ultomiris in severe COVID-19 casesPharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined Share XAlexion trials rare disease drug Ultomiris in severe COVID-19 caseshttps://pharmaphorum.com/news/alexion-trials-rare-disease-drug-ultomiris-in-severe-covid-19-cases/
Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
Alexion’s Soliris follow-up Ultomiris snares EU approvalAlexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that Share XAlexion’s Soliris follow-up Ultomiris snares EU approvalhttps://pharmaphorum.com/news/alexions-soliris-follow-up-ultomiris-snares-eu-approval/
